Wed Sep 18 05:26:54 UTC 2024: ## Crinetics Pharmaceuticals Receives Positive Analyst Ratings, Stock Price Potential Up 69%

**New York, NY** – Crinetics Pharmaceuticals (NASDAQ: CRNX) continues to garner optimistic attention from Wall Street analysts, with several reiterating “buy” ratings and boosting price targets. Cantor Fitzgerald maintains an “overweight” rating on the stock, predicting a potential 69.84% upside from its current price with a $90.00 price target.

Other analysts echo this sentiment, with JMP Securities reaffirming a “market outperform” rating and a $80.00 price objective, Oppenheimer reasserting an “outperform” rating with a $73.00 price target, and Robert W. Baird upgrading their price target to $62.00 and maintaining an “outperform” rating. JPMorgan Chase & Co. also increased their price objective to $54.00 and retained an “overweight” rating, while HC Wainwright boosted their target price to $69.00 and reiterated a “buy” rating.

The overall consensus among analysts is “Moderate Buy” with a consensus price target of $68.55.

Crinetics Pharmaceuticals focuses on developing treatments for rare endocrine diseases and tumors. Their lead product candidate, paltusotine, is currently in Phase 3 clinical trials for acromegaly and Phase 2 trials for carcinoid syndrome associated with neuroendocrine tumors.

While the company reported a quarterly loss of $0.94 per share, missing analyst estimates, revenue came in at $0.40 million, slightly lower than expectations. However, the company remains confident in its future prospects, particularly with paltusotine’s promising clinical trial progress.

Institutional investors continue to show strong interest in the company, with several hedge funds and other institutions increasing their holdings in recent quarters.

Crinetics Pharmaceuticals’ strong fundamentals and positive analyst outlook suggest a potential for significant stock price growth. Investors are advised to monitor the company’s progress in clinical trials and any potential regulatory approvals for paltusotine in the coming months.

Read More